Carrier heat pump system control manual

Global Intelligent Pump and Control Systems Market to Reach US$682. 4 Million by the Year 2027. Amid the COVID-19 crisis, the global market for Intelligent Pump and Control Systems estimated at US$501.New York, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Intelligent Pump and Control Systems Industry" - 7 Million in the year 2020, is projected to reach a revised size of US$682.4 Million by 2027, growing at a CAGR of 4.5% over the period 2020-2027.Centrifugal Pumps, one of the segments analyzed in the report, is projected to grow at a 4.3% CAGR to reach US$434.8 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Positive Displacement Pumps segment is readjusted to a revised 4.9% CAGR for the next 7-year period. This segment currently accounts for a 35.4% share of the global Intelligent Pump and Control Systems market. The U.S. Accounts for Over 29.4% of Global Market Size in 2020, While China is Forecast to Grow at a 4.2% CAGR for the Period of 2020-2027 The Intelligent Pump and Control Systems market in the U.S. is estimated at US$147.7 Million in the year 2020. The country currently accounts for a 29.44% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$120.9 Million in the year 2027 trailing a CAGR of 4.2% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.3% and 3.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR while Rest of European market (as defined in the study) will reach US$120.9 Million by the year 2027.We bring years of research experience to this 6th edition of our report. The 176-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, ABB GroupAptiv PLCBosch Rexroth AGDana Brevini S.p.A.Emersion Electric Co.Flowserve CorporationGrundfos Holding A/SIfm Efector, Inc.Rockwell Automation, Inc.ROHM Co., Ltd.Sulzer Ltd.Yaskawa Electric CorporationRead the full report: I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Intelligent Pump and Control Systems Competitor Market Share Scenario Worldwide (in %): 2018E 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Intelligent Pump and Control Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 2: World Historic Review for Intelligent Pump and Control Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 3: World 15-Year Perspective for Intelligent Pump and Control Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027 Table 4: World Current & Future Analysis for Centrifugal Pumps by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 5: World Historic Review for Centrifugal Pumps by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 6: World 15-Year Perspective for Centrifugal Pumps by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 7: World Current & Future Analysis for Positive Displacement Pumps by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 8: World Historic Review for Positive Displacement Pumps by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 9: World 15-Year Perspective for Positive Displacement Pumps by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 10: World Current & Future Analysis for Water and Wastewater Industry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 11: World Historic Review for Water and Wastewater Industry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 12: World 15-Year Perspective for Water and Wastewater Industry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 13: World Current & Future Analysis for Oil and Gas Industry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 14: World Historic Review for Oil and Gas Industry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 15: World 15-Year Perspective for Oil and Gas Industry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 16: World Current & Future Analysis for Chemical and Petrochemical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 17: World Historic Review for Chemical and Petrochemical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 18: World 15-Year Perspective for Chemical and Petrochemical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 Table 19: World Current & Future Analysis for Power Industry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 20: World Historic Review for Power Industry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 21: World 15-Year Perspective for Power Industry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Intelligent Pump and Control Systems Market Share (in %) by Company: 2018 & 2027 Market Analytics Table 22: USA Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 23: USA Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 24: USA 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 25: USA Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 26: USA Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 27: USA 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 CANADA Table 28: Canada Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 29: Canada Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 30: Canada 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 31: Canada Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 32: Canada Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 33: Canada 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 JAPAN Table 34: Japan Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 35: Japan Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 36: Japan 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 37: Japan Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 38: Japan Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 39: Japan 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 CHINA Table 40: China Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 41: China Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 42: China 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 43: China Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 44: China Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 45: China 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 EUROPE Market Facts & Figures European Intelligent Pump and Control Systems Market: Competitor Market Share Scenario (in %) for 2018 & 2027 Market Analytics Table 46: Europe Current & Future Analysis for Intelligent Pump and Control Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027 Table 47: Europe Historic Review for Intelligent Pump and Control Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 48: Europe 15-Year Perspective for Intelligent Pump and Control Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2018 & 2027 Table 49: Europe Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 50: Europe Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 51: Europe 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 52: Europe Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 53: Europe Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 54: Europe 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 FRANCE Table 55: France Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 56: France Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 57: France 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 58: France Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 59: France Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 60: France 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 GERMANY Table 61: Germany Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 62: Germany Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 63: Germany 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 64: Germany Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 65: Germany Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 66: Germany 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 ITALY Table 67: Italy Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 68: Italy Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 69: Italy 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 70: Italy Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 71: Italy Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 72: Italy 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 UNITED KINGDOM Table 73: UK Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 74: UK Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 75: UK 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 76: UK Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 77: UK Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 78: UK 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 REST OF EUROPE Table 79: Rest of Europe Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 80: Rest of Europe Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 81: Rest of Europe 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 82: Rest of Europe Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 83: Rest of Europe Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 84: Rest of Europe 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 ASIA-PACIFIC Table 85: Asia-Pacific Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 86: Asia-Pacific Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 87: Asia-Pacific 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 88: Asia-Pacific Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 89: Asia-Pacific Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 90: Asia-Pacific 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 REST OF WORLD Table 91: Rest of World Current & Future Analysis for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 92: Rest of World Historic Review for Intelligent Pump and Control Systems by Type - Centrifugal Pumps and Positive Displacement Pumps Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 93: Rest of World 15-Year Perspective for Intelligent Pump and Control Systems by Type - Percentage Breakdown of Value Sales for Centrifugal Pumps and Positive Displacement Pumps for the Years 2012, 2018 & 2027 Table 94: Rest of World Current & Future Analysis for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through 2027 Table 95: Rest of World Historic Review for Intelligent Pump and Control Systems by End-Use - Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017 Table 96: Rest of World 15-Year Perspective for Intelligent Pump and Control Systems by End-Use - Percentage Breakdown of Value Sales for Water and Wastewater Industry, Oil and Gas Industry, Chemical and Petrochemical and Power Industry for the Years 2012, 2018 & 2027 IV. COMPETITION Total Companies Profiled: 71Read the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001(Bloomberg) -- The market's reflationistas are getting a second wind, as a string of solid economic numbers and the prospect of more stimulus raise the chances of a revival in trades linked to rebounding growth and prices.A gauge of U.S. inflation expectations climbed to an eight-year high Tuesday, the Bloomberg Commodity Spot Index reached its highest since 2012 and Treasury yields saw gains across the curve.Reflation believers have warmed to reports showing soaring home prices and consumer confidence. They are also looking ahead to President Joe Biden's pitch for a large social-spending package to Congress Wednesday and a renewed commitment from the Federal Reserve to allow inflation to run hot."The inflation question will continually return to investors' minds this year," said Andy Wong, senior investment manager of the international multi-asset team at Pictet Asset Management in Hong Kong. "The U.S. household balance sheet is the healthiest it has been for years, and 'excess savings meets disrupted supply chains' means dislocation in supply and demand."The reflation trade had hit a wall this month, with havens such as Treasuries rallying and cyclical shares underperforming as spikes in Covid-19 infection rates around the world forced renewed lockdowns in major economies. But the relentless rise in commodity prices has pushed inflation expectations out of their lull and some strategists expect the rally to continue.Goldman Says Commodities Will Power On as Oil Demand Leaps The sharp increases in the cost of materials are motivating companies such as Procter & Gamble Co. and Chipotle Mexican Grill Inc. to pass on costs to consumers -- moves that raise questions about the Fed's assurances that any bump in inflation will be short-lived. The 10-year breakeven rate, a proxy for where investors see annual inflation rates over the next decade, topped 2.4% Tuesday -- the highest since April 2013."There's some skepticism there as to whether it is transitory, given the delays in supply chains and potentially some productive capacity destruction as a result of lockdowns," said Anthony Doyle, global cross-asset investment specialist at Fidelity Investment Management in Sydney.Gundlach Says Fed Is Guessing That Inflation Will Be TransitoryStill, not everyone is ready to pile back into the reflation trades that gripped markets earlier this year. An MSCI Inc. gauge of global value shares -- which have high exposure to economic growth -- has lagged its more defensive growth counterpart by nearly 4 percentage points this month and has barely budged this week.BlackRock Inc. has turned neutral from overweight on U.S. inflation-linked bonds after the recent rebound in inflation expectations. The world's largest asset manager has also cut its short positioning in Treasuries.BlackRock Cuts Inflation-Haven Bond Bet, Stays Bullish on StocksNevertheless, it's harder to dismiss inflation risks given the positive surprises in recent economic reports."All of the better data points to a higher-inflation narrative that the market is reflecting," said Rob Daly, director of fixed income for Glenmede Investment Management in Philadelphia.(Updates throughout.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.The NCAA Board of Governors casually extended Mark Emmert's tenure as an afterthought at the tail-end of a lengthy news release — perhaps the most telling sign of how bad of a decision it was.(Bloomberg) -- Oil edged higher after OPEC+ confirmed it would proceed with plans to add more barrels to the market, despite a virus resurgence in some regions including India clouding the demand outlook.Futures in New York traded above $63 a barrel after advancing the most in almost two weeks on Tuesday. An OPEC+ committee agreed that the alliance should press ahead with its road map for increasing supply over the next three months. The coalition raised its estimates for demand growth this year on Monday, while BP Plc also pointed to signs of a robust recovery.Oil demand is expected to post the biggest ever jump over the next six months as vaccination rates surge in Europe, according to Goldman Sachs Group Inc., which reiterated its forecast for global benchmark Brent crude to reach $80 a barrel during the third quarter of this year.The global oil market recovery is being driven by China and the U.S., with positive signs emerging from parts of Europe. An accelerating vaccination program is expected to increase mobility and consumption further, although crude prices have whipsawed near $60 a barrel recently as Covid-19 flare-ups in India and Brazil raised concerns about near-term demand.OPEC+ will skip its scheduled ministerial meeting on Wednesday after sticking with its plan to hike supply by 2 million barrels a day over the next three months, according to delegates. The next gathering will be in early June, a delegate said, asking not to be identified as the information isn't public."Oil demand has yet to recover to pre-virus levels and we see room for further tightening of the oil supply balance in the second half," said Howie Lee, an economist at Oversea-Chinese Banking Corp. "The biggest swing driver for oil right now is the state of coronavirus outbreak in India."The prompt timespread for Brent was 59 cents a barrel in backwardation -- a bullish market structure where near-dated contracts are more expensive than later-dated ones. That's down from 69 cents at the end of last week.See also: U.S. Truck Boom Shows Why Oil's Demand Comeback Is Here to StayOil demand is expected to expand by 5.2 million barrels a day over the next six months, which would be 50% more than the next largest increase over the same time frame since 2000, Goldman Sachs said in a note. Commodity markets have looked through a sharp rise in Covid-19 cases in India, the bank added.The American Petroleum Institute, meanwhile, reported U.S. crude stockpiles expanded by 4.32 million barrels last week, according to people familiar with the data. If confirmed by government figures Wednesday, it would be a second straight weekly gain. The API reported a drop in gasoline inventories.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.This Benefit Cosmetics 3-piece set is a total steal.It was a historic night on Wheel of Fortune Tuesday night, when Laura Trammell, a sixth grade teacher from Mission Viejo, became the first person ever to win a house during the bonus round during Wheel of Fortune's "Home Sweet Home" giveaway, which is happening every night this week in partnership with Minto and Latitude Margaritaville. Heading into the bonus round, Trammell had already won $23,690 including a trip to St. Thomas for a tropical island getaway. However, after solving the bonus round puzzle with the phrase "I caught a glimpse," Trammell caught a glimpse of her future life of sipping margaritas, when she found out she had landed on the home envelope during her spin, which won her a new crib valued at $375,000 in Margaritaville. "This is just nuts," said host Pat Sajak. Trammell, who was initially speechless, later told Sajak, "I am beyond excited, I'm still in shock. I still can't believe it just happened." Meanwhile, viewers on social media were also speechless and shocked about Trammell's historic win, and many took to Twitter to congratulate her: Ultimately, Trammell walked away with $398,690 in cash and prizes, and Vanna White walked away with her eye intact, as Sajak explained, "First thing, I have to tell you that, when you won, Vanna was running across the stage, and the confetti came out, and you got whacked in the head by a clump of confetti!" "Thank goodness, it wasn't my eye," White replied to Sajak, who exclaimed, "You could've put your eye out!"Haryana Chief Minister Manohar Lal Khattar has said it was pointless to argue over COVID-19 fatality figures as the dead won't came back to life, and the focus should be on helping those suffering now.Protection was seen from around 14 days after vaccination, with similar levels regardless of a person's age.The FTSE 100 was set to gain in early trading today as global markets were set to celebrate bumper profits last night from Microsoft and Google owner Alphabet. The FTSE 100 was being called up 27 points to 6955 by traders on the IG platform. HSBC and BP were the big gainers in yesterday's session after they both beat forecasts with their earnings figures.Software from Medidata - a U.S. clinical trials business the group acquired for $5.8 billion in 2019 - was used in nearly two-thirds of COVID-19 trials and helped triple sales in its life sciences division last year. "We are seeing strong momentum in life sciences, led by Medidata where software revenue increased 20% in the first quarter driven by Rave in clinical data management, Patient Cloud and Acorn AI," finance chief Pascal Daloz said in a statement. The group expects revenues from Medidata, whose software was used in trials for vaccines developed by Pfizer-BioNTech,, Moderna, and Britain's AstraZeneca, to grow just under 15% for the full year.Dystopian drama is returning to Hulu on 28 AprilHMST earnings call for the period ending March 31, 2021.Nasdaq CopenhagenLondon Stock ExchangeOther stakeholders 28 April 2021 Ringkjøbing Landbobank's report for the first quarter of 2021 With core earnings of DKK 368 million and profit before tax of DKK 354 million, the bank delivers a good start to 2021. The profit before tax is equivalent to a return of 17.4% p.a. on equity. Core earnings (DKK million)Q1 2021Q1 20202020201920182017 2016Total core income6005412,1792,1162,0011,9171,861Total expenses and depreciation2031987888058668 45815Core earnings before impairment charges for loans3973431,3911,3111,1351,0721,046Impairment charges for loans etc.-29-75-223-100-43-70-211Core earnings3682681,1681,2111,0921,002835Result for the portfolio etc.-10-70-9+49+77+84+78Special costs4415152172222Profit before tax3541941,1441,2459521,064891 Highlights of the first quarter of 2021 The profit before tax is DKK 354 million, equivalent to a return of 17.4% p.a. on equityCore income increases by 11% to DKK 600 million following a high level of activityExpenses increase by 3% to DKK 203 millionThe rate of costs decreases to 34% in the quarterA big increase in new customers and a high level of activity result in growth of 3% in the bank's loans, both compared to the end of March 2020 and in the first quarter of 2021 Image in top 3 and customer satisfaction remains high Yours sincerely Ringkjøbing Landbobank John Fisker Attachment Q1 Rapport 2021 - ENWednesday briefing: Fauci – wealthy nations must help IndiaCall for rich countries to assume responsibility over Covid crisis … Tories urge Johnson to explain flat refurbishment … and the end of bras Funeral pyres at Ghazipur cremation ground, Delhi. Photograph: Naveen Sharma/Sopa Images/Rex/Shutterstock» Income amounted to SEK 807 million (837).» The operating surplus amounted to SEK 524 million (558).» Profit from property management amounted to SEK 309 million (324).» Profit before tax amounted to SEK 909 million (882) and net profit, attributable to the parent company's share-holders, totalled SEK 796 million (656), corresponding to SEK 0.67 (0.62) per ordinary share.» Investments amounted to SEK 490 million. Project development, including development of building rights, contributed to increases in value of properties of SEK 122 million (97). In total, changes in value of properties amounted to SEK 406 million (593).» During the quarter, 3 properties were taken possession of for SEK 152 million and 13 properties were divested and handed over for SEK 700 million. On 31 March 2021, the fair value of Klövern's 341 properties, excluding properties classified as current assets, amounted to SEK 58,289 million. In addition, there are 9 properties classified as current assets which are reported at a value of SEK 1,014 million and have an estimated fair value of SEK 1,742 million.» The interest coverage ratio amounted to 2.7 (2.5), leverage to 50 per cent (50) and the adjusted equity ratio to 43.9 per cent (43.2).» The net reinstatement value (NRV) per ordinary share amounted to SEK 20.78.» On 25 March 2021, Rutger Arnhult left Klövern's board of directors and his position as CEO. The board has appointed Peeter Kinnunen, Klövern's head of transactions, as acting CEO.» On 29 March 2021, Corem Property Group AB (publ) announced a public offer with consideration in the form of newly issued shares in Corem to the shareholders of Klövern AB (publ). An offer document is expected to be published by the Offeror on or around 10 May 2021. The acceptance period for the offer is expected to end on 8 June 2021. Klövern's board of directors, together with its advisors, will evaluate the Offer and will publish its opinion on the Offer at the latest two weeks prior to the end of the acceptance period. Statement by the CEOStable earnings in a recovering marketLike last year, 2021 will continue to be marked by the ongoing pandemic and the recovery from the same. However, I can note that the ongoing vaccinations, and a better starting point for the Swedish economy than in many other countries both contribute to good hope for a gradual normalization. For Klövern, the first quarter has been eventful in many ways. After having been head of transactions in the company for almost a decade, I am pleased to have also assumed the role as acting CEO. During the quarter, Corem Property Group has also announced a public offer to the shareholders of Klövern.STABLE EARNINGSKlövern is reporting stable earnings for the first quarter which are fully in line with our expectations taking into account a cold and snowy winter as well as continued lower-than-normal parking revenues. Once again, we can note that the composition of the portfolio and the diversified customer base have provided stability during the pandemic. Profit from property management amounted to SEK 309 million and after positive changes in value of properties of SEK 406 million, profit before tax was SEK 909 million. THE OFFER FROM COREMAt the end of March, Corem announced a public offer to the shareholders of Klövern. The process is completely controlled by the offeror so that the offer does not affect ongoing work at Klövern. It is business as usual. The acceptance period for the offer is expected to end on 8 June. Klövern's board will make a statement on the offer at the latest two weeks before the end of the acceptance period. POSITIVE SIGNALS ON ECONOMIC RECOVERYThe swift downturn of the Swedish and the global economy during 2020 is historic. The consequences can be seen, inter alia, in increased unemployment. However, an increasingly positive picture of the world economy is now being painted. In the United States, for instance, extensive stimulation packages and efficient vaccination have contributed to positive macro signals. The Swedish economy's resilience appears impressive from a European perspective and there is therefore every reason to be optimistic about the continued recovery during 2021. At the beginning of the year, the transaction market has been very strong with continued falling yield requirements while the rental market is more hesitant. NET MOVING-IN REFLECTS A HESITANT MARKETDuring the first quarter, net moving-in amounted to SEK –16 million and net letting to SEK –17 million. It is usually the case that more vacations and terminations take place during the first quarter than in subsequent quarters and the outcome was expected given that the letting climate is still hesitant in many cities. During the quarter, we have, however, welcomed a number of new tenants, including Eurofins which leases over 900 sq.m. in Uppsala and a number of new tenants at the property Solna Gate in Stockholm that together lease over 1,800 sq.m. During the quarter, lease contracts have also been signed with Matthew Kenney for approximately 730 sq.m. of restaurant space in New York, with Pharmadanmark for approximately 1,000 sq.m. in Copenhagen and with Servistore for around 1,600 sq.m. in Nyköping. Klövern is in a very project-intensive phase which is expected to have a large positive effect on net letting during the coming two years. A FOCUSED PROPERTY PORTFOLIOBased on our strategy, we have a clear picture of the growth locations and segments that we want to focus Klövern's long-term ownership on. During the quarter, 12 properties were divested, mainly with warehouse/logistics premises, to Mileway in a transaction that took place at a premium of 21 per cent in relation to book value. We have also taken possession of three properties that complement the existing portfolios in Lund and Uppsala and in the exciting urban development area Söderstaden in Stockholm. During the second quarter, a relatively small but strategically important add-on acquisition which improves the efficiency of the future project on Park Avenue in New York, is planned to be taken possession of. The aggregate value of the property portfolio at the end of the quarter, excluding properties classified as current assets in Tobin Properties, was SEK 58 billion, of which the international portfolio in Copenhagen and New York accounted for 16 per cent. INTENSIVE PROJECT DEVELOPMENTKlövern's project and urban development activities are extensive with a number of major ongoing projects and a very interesting pipeline. As at 31 March, development properties accounted for 16 per cent of the total property value. During the last four quarters, investments amounted to SEK 2,399 million and, in addition during the same period, Klövern's project development, including development of building rights, contributed to increases in value of properties of SEK 538 million. Klövern's two largest ongoing new production projects are two office buildings of the highest quality in attractive locations in Manhattan. In New York, the letting market, as in the rest of the world, has seen less activity due to the pandemic and it will therefore take slightly longer to complete lettings associated with these projects. It is, however, gratifying that there are indications of a recovery. Everyone over 16 years of age is now entitled to vaccine in New York and it is planned for all public employees to return to their work places in May. Exciting work is taking place at Uppsala Business Park focused on development of a living city neighbourhood and a location for innovation in life science. There is great interest in the area and we have extensive project plans for the coming years. Already now, Uppsala Business Park offers unique premises with laboratories and facilities for manufacturing of pharmaceuticals. LONG-TERM SUSTAINABLE FINANCINGWe are continuously working to secure long-term sustainable financing. During the quarter, we have issued SEK 2,500 million green bonds under Klövern's MTN programme. Klövern now has green bonds amounting to a total of SEK 6,850 million. In the sphere of sustainability, it may also be mentioned that the over 30,000 sq.m. large, fully let property at Kalvebod Brygge in central Copenhagen which will be taken possession of at the beginning of May has obtained energy classification A. FOCUS ON ECONOMIC RECOVERYWe entered the second quarter backed up by stable earnings and with full focus on ongoing activities at the same time as we are monitoring developments associated with Corem's offer. Ahead of me, I see an eventful year marked by a gradual normalization where we can again have physical meetings, not least at the office, to create new business in a climate of economic recovery. Even though both our and other's business operations have made good progress with many digital meetings, they can never completely replace physical meetings. Human beings are social creatures and physical meetings are needed to build relationships, develop the corporate culture and create new business. Peeter Kinnunen, Acting CEOKlövern AB (publ) For additional information, please contact: Peeter Kinnunen, Acting CEO, +46 76 855 67 03, peeter.kinnunen@klovern.se Lars Norrby, IR, +46 76 777 38 00, lars.norrby@klovern.se Klövern is a real estate company committed to working closely with customers to offer them attractive premises in growth regions. Klövern is listed on Nasdaq Stockholm. For further information, see www.klovern.se.Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Phone: +46 10 482 70 00. Email: info@klovern.se.This information is information that Klövern AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of the contact persons set out above at 07.30 CEST on 28 April 2021. This interim report has been published in Swedish and in English. In the event of a discrepancy between the language versions, the Swedish version shall take priority. Attachment Read the Q1 2021 report here (pdf)Paris, April 28, 2021 Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER. Q1 2021 sales increase of 2.4% at CER driven by growth drivers Dupixent® and Vaccines Specialty Care sales grew 15.3%, due to strong Dupixent® performance (+45.6% to €1,047 million) and oncology launchesVaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere General Medicines core assets grew 4.4%, while GBU sales were down 3.8% CHC decreased 7.3% due to COVID related stocking in Q1 2020 and low demand for cough and cold brands in Europe Q1 2021 business EPS(1) growth at CER driven by efficiency and sales performance, supported by a one-time payment Business EPS(1) was €1.61 up 5.2% on a reported basis and up 15.0% at CERBusiness EPS(1) includes an incremental 8 cents due to a payment related to the termination of a collaboration in JapanIFRS EPS was €1.25 Progress on implementation of the Corporate Social Responsibility strategy Sanofi has become a member of the top five companies of the 2021 Access to Medicine indexSanofi announced Sanofi Global Health, a newly formed non-profit unit within the company, a new cornerstone of its CSR strategy Full-year 2021 business EPS guidance affirmed Sanofi expects 2021 business EPS(1) to grow high single digit(2) at CER, barring unforeseen major adverse events. Applying average April 2021 exchange rates, the currency impact on 2021 business EPS is estimated to be between -4% to -5%. Sanofi Chief Executive Officer, Paul Hudson, commented: "Our strong first-quarter performance is the result of the continued execution of our Play to Win strategy to drive growth and bring innovative medicines to patients. Dupixent® continues its outstanding performance with impressive growth in the U.S. and strong uptake in global markets, including China. Vaccines delivered growth in its core segments. We initiated and completed enrollment of our Phase 2 study for our recombinant COVID-19 vaccine candidate in the first quarter and results are expected next month. Following the communication of our ESG strategy at the end of 2020 and embedding it into our business priorities, we have recently created the Sanofi Global Health Unit, dedicated to increasing access to 30 medicines considered essential by the WHO. Sanofi is uniquely positioned to make this difference to society, which can be scaled and sustained over time, given our portfolio of essential medicines and broad geographic presence." Q1 2021 Change Change at CER IFRS net sales reported €8,591m -4.3% +2.4% IFRS net income reported €1,566m -7.0% _ IFRS EPS reported €1.25 -7.4% _ Free cash flow(3) €1,925m +23.6% _ Business operating income €2,638m +4.0% +13.3% Business net income(1) €2,017m +5.1% +14.7% Business EPS(1) €1.61 +5.2% +15.0% Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 7)(1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (definition in Appendix 7). The consolidated income statement for Q1 2021 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) 2020 restated business EPS was €5.86; (3) Free cash flow is a non-GAAP financial measure (definition in Appendix 7). 2021 first-quarter Sanofi sales ----------------------------Unless otherwise indicated, all percentage changes in sales in this press release are stated at CER1 --------------------------- In the first quarter of 2021, Sanofi sales were €8,591 million, down 4.3% on a reported basis. Exchange rate movements had a negative effect of 6.7 percentage points, mainly driven by the decrease of the U.S. dollar, Brazilian real, Russian ruble, Turkish lira, and Argentine peso and Japanese yen. At CER, Sanofi sales increased 2.4%. Global Business Units First-quarter 2021 operating income First-quarter business operating income (BOI) increased 4.0% to €2,638 million. At CER, BOI increased 13.3%. The ratio of BOI to net sales increased 2.4 percentage points to 30.7% versus the prior year. Pharmaceuticals First-quarter 2021 Pharmaceutical sales increased 3.8% to €6,563 million, with double-digit growth of the Specialty Care portfolio mainly driven by the strong performance of Dupixent® which largely offset lower sales in General Medicines in Europe and the U.S. Specialty Care Dupixent Net sales (€ million) Q1 2021 Change at CER Total Dupixent® 1,047 +45.6 % In the first quarter, Dupixent® (collaboration with Regeneron) sales were strong despite the COVID-19 environment and increased 45.6% to €1,047 million. In the U.S., Dupixent® sales of €793 million (up 41.6%) were driven by continued strong demand in atopic dermatitis (AD) in adult, adolescent patients, and children aged 6 to 11 years, continued uptake in asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent® total prescriptions (TRx) increased 51% (year-over-year) and new-to-brand prescriptions (NBRx) grew 16% despite fewer in-person physician visits which remain below the pre-COVID level. In Europe, first-quarter Dupixent® sales grew 52.2% to €137 million reflecting continued growth in AD in key countries and additional launches in asthma in European markets. In Japan, sales were €59 million (up 53.7%), where strong demand was moderated by the government price decrease implemented in April 2020. Dupixent® was approved in China for the treatment of adults with moderate-to-severe AD in June 2020 and is listed on the NRDL (National Reimbursement Drug List) as of March 2021. At the end of the first quarter, Dupixent® was launched in 49 countries with approximately 260 000 patients on therapy. Neurology and Immunology Net sales (€ million) Q1 2021 Change at CER Aubagio® 500 -1.1 % Lemtrada® 24 -44.9 % Kevzara® 57 +10.9 % Total Neurology and Immunology 581 -3.4 % In the first-quarter, Neurology and Immunology sales were down 3.4% to €581 million, impacted primarily by the decline of Lemtrada® sales. Aubagio® sales decreased 1.1% in the first quarter to €500 million, due to lower sales in the U.S. reflecting increased competition partially offset by demand growth partly related to clinical trial supply and price upside in Europe. First-quarter Lemtrada® sales decreased 44.9% to €24 million, primarily due to the COVID-19 pandemic, which has led to a decrease in infused immune reconstitution therapies such as Lemtrada®. First-quarter Kevzara® (collaboration with Regeneron) sales were up 10.9% to €57 million driven by Europe and Rest of the World which largely offset lower U.S. sales reflecting the recent strategic decision to reduce promotional efforts. Rare Disease Net sales (€ million) Q1 2021 Change at CER Myozyme® / Lumizyme® 235 +0.8 % Fabrazyme® 208 +4.7 % Cerezyme® 178 +4.2 % Aldurazyme® 66 +7.5 % Cerdelga® 62 +13.8 % Others Rare Disease 21 +10.0 % Total Rare Disease 770 +4.4 % In the first quarter, Rare Disease sales increased 4.4% to €770 million, primarily driven by higher demand particularly in Rest of the World (up 10.2%). Sales in Europe increased 0.4% and compared to a high base in the first quarter of 2020 due to an inventory build related to the COVID-19 environment. First-quarter Cerezyme® sales increased 4.2% to €178 million, driven by strong growth in Rest of the World (up 18.4%). First-quarter Cerdelga® sales increased 13.8% to €62 million driven by new patient accruals in the three regions. Sales of the Gaucher franchise (Cerezyme® + Cerdelga®) increased 6.5% (to €240 million) in the first quarter. First-quarter Myozyme®/Lumizyme® sales increased 0.8% to €235 million supported by new patient accruals in the U.S. (up 11.5%) which offset lower sales in Europe and negative phasing effect in Rest of the World. First-quarter Fabrazyme® sales increased 4.7% to €208 million driven by higher sales in Rest of the World and Europe. In the U.S. sales decreased 2.9% reflecting lower treatment compliance during the COVID-19 pandemic. Oncology Net sales (€ million) Q1 2021 Change at CER Jevtana® 126 -2.9 % Fasturtec® 35 +8.6 % Libtayo® 26 +125.0 % Sarclisa® 34 +3400.0 % Total Oncology 221 +25.8 % First-quarter Oncology sales increased 25.8% to €221 million, driven by the Sarclisa® and Libtayo® launches. First-quarter Jevtana® sales decreased 2.9% to €126 million following the entry of generic competition in Europe (down 11.8%) at the end of March. In the U.S., sales were up 5.0%. In the U.S., the Jevtana® composition of matter patent will expire in September 2021. From May to July 2020, Sanofi filed patent infringement suits against all generic filers on Jevtana® under Hatch-Waxman in the U.S. District Court for the District of Delaware asserting two method of use patents (US 10,583,110 and US 10, 716,777), both of which expire in October 2030. Sanofi has reached settlement agreements with some of the defendants and the suit against the remaining defendants currently stayed. In Europe, generic competition has started in certain countries after the expiration of Jevtana®'s market exclusivity in March 2021. Libtayo® (collaboration with Regeneron) sales were €26 million (up 125.0%) in the first quarter driven by increased demand in metastatic cutaneous squamous cell carcinoma (CSCC) as well as additional country launches. In February, Libtayo® was approved in two new indications in the U.S. as a monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50% and for patients with advanced basal cell carcinoma. Libtayo® sales in the U.S. are reported by Regeneron. Sarclisa® was approved in March 2020 in the U.S. for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and in June by the European Commission in certain adults with RRMM. First-quarter Sarclisa® sales were €34 million driven by additional country launches. First-quarter sales in the U.S. and in Europe were €12 million and €13 million, respectively. In Rest of the World sales (€9 million) were driven by a strong

performance in Japan. At the end of March, the FDA approved Sarclisa® in combination with carfilzomib and dexamethasone for patients with relapsed multiple myeloma. Rare Blood Disorder Net sales (€ million) Q1 2021 Change at CER Eloctate® 134 -9.9 % Alprolix® 100 -1.8 % Cablivi® 38 +66.7 % Total Rare Blood Disorder 272 -0.7 % In the first quarter, Rare Blood Disorder franchise sales were down 0.7% (€272 million). Excluding industrial sales to Sobi, first-quarter sales were up 5.1% driven by Alprolix® and Cablivi® performance which more than offset Eloctate® sales decrease in the U.S. As already communicated, Alprolix® and Eloctate® industrial sales to Sobi are expected to be significantly lower in 2021 than in 2020. Eloctate® sales were €134 million in the first quarter, down 9.9%. Excluding industrial sales to Sobi, Eloctate sales were down 3.4% mainly due to lower U.S. sales (-5.0%) as a result of ongoing competitive pressure. Sales in the Rest of the World were down 23.8% reflecting lower industrial sales to Sobi. First-quarter Alprolix® sales were down 1.8% to €100 million. Excluding industrial sales to Sobi, Alprolix sales were up 3.0%, mainly driven by patient switches from standard half-life factors and prophylaxis conversion. Sales in the Rest of the World were down 19.2% reflecting lower industrial sales to Sobi. Cablivi® for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and acute blood disorder, generated sales of €38 million (up 66.7%) in the first quarter of which €22 million from the U.S. (up 60%) driven by increase disease and product awareness as well as adoption of new ISTH (International Society on Thrombosis and Haemostasis) TTP guidelines. In Europe, sales were €15 million (up 66.7%) driven by new country launches. Globally, diagnosis of the disease and product awareness remain impacted by the COVID-19 environment. General Medicines General Medicines sales were down 3.8% to €3,672 million in the first quarter. Sales of the core assets2 were 1,474 million up 4.4% (and up 6.3% excluding Praluent® U.S. sales3), driven by strong performance of Lovenox®. Non-core assets sales were €2,010 million, down 9.9% reflecting notably portfolio streamlining, lower Lantus® and Aprovel®/Avapro® sales and some negative COVID-19 impact. First-quarter industrial sales were €188 million up 8.8%. Diabetes Net sales (€ million) Q1 2021 Change at CER Lantus® 652 -3.7 % Toujeo® 253 +5.1 % Total glargine 905 -1.4 % Soliqua® 44 +29.7 % Other diabetes 226 -7.3 % Total Diabetes 1,175 -1.7 % In the first quarter, global Diabetes sales decreased 1.7% to €1,175 million. The growth in the Rest of the World (up 5.3%) was driven by Lantus®, Toujeo® launch in China and Soliqua® performance. In the U.S., the Diabetes sales decrease 5.3%. In Europe, sales decreased 10.2% largely affected by patient stockpiling related to the COVID-19 environment in the first quarter of 2020. First-quarter Toujeo® sales increased 5.1% to €253 million driven by the launch in China. Lower sales in Europe reflected the high base in the first quarter 2020 due to patient stockpiling. In the U.S., Toujeo® sales were stable with volume growth offsetting average price decrease. Lantus® sales were €652 million, down 3.7% in the first quarter, mainly due to a continued decline in average U.S. net price, increasing usage of Toujeo®, biosimilar glargine competition and lower sales in Europe (patient stockpilling in the first quarter of 2020). In Rest of the World, sales increased 4.9%. First-quarter Soliqua® sales increased 29.7% to €44 million driven by growth in the three regions and notably by launches in Rest of the World (up 44.4%) and performance in the U.S. (up 27.3%) Cardiovascular and Established Rx Products Net sales (€ million) Q1 2021 Change at CER Lovenox®* 401 +30.4 % Plavix®* 251 -4.0 % Aprovel®/Avapro® 101 -39.7 % Thymoglobulin® 80 +1.2 % Multaq® 72 -3.7 % Praluent® 56 -20.5 % Mozobil® 52 +1.9 % Generics 206 +3.5 % Other 1,090 -12.2 % Total Cardiovascular and Established Rx Products 2,309 -5.6 % *Excluding Auto generics In the first quarter, Cardiovascular and Established Rx Products sales decreased 5.6% to €2,309 million reflecting strong Lovenox® growth more than offset in particular by lower sales of Aprovel®/Avapro®, divestments and some COVID impact. First-quarter Lovenox® sales increased 30.4% to €401 million, driven by Rest of the World (up 50.7%), and Europe (up 10.5%) reflecting demand increase driven by recent guidelines recommending the use of low molecular weight heparins in hospitalized COVID-19 patients which more than offset biosimilar competition and postponed procedures. Plavix® sales were down 4.0% in the first quarter to €251 million mainly reflecting lower sales in Europe (down 23.7%) and Japan. In China, first-quarter Plavix® sales were €117 million, up 0.8%. First-quarter Aprovel®/Avapro® sales were down 39.7%% to €101 million, primarily reflecting a short-term supply constraint. First-quarter Praluent® sales decreased 20.5% to €56 million, due to lower sales in the U.S. reflecting the restructuring of the collaboration with Regeneron which was effective on April 1, 2020. Sanofi has sole responsibility for Praluent® outside the U.S. while Regeneron has sole responsibility for Praluent® in the U.S. Excluding U.S. sales3 , Praluent® sales grew 26.8% driven by a strong performance in Europe (up 20.0%) and Rest of the World (up 45.5%) driven by the launch in China. Praluent® was relaunched in Germany at the beginning of April 2021. Multaq® sales were €72 million, down 3.7% in the first quarter due to lower sales in the U.S. impacted by the COVID-19 environment. Pharmaceuticals business operating income In the first quarter, business operating income (BOI) of Pharmaceuticals decreased 4.6% to €2,515 million (up 2.9% at CER). The ratio of BOI to net sales decreased by 0.7 percentage points to 38.3%. At CER, the ratio decreased 0.4 percentage points reflecting higher SG&A spends as well as increased “Other operating expenses” mainly reflected Regeneron MAbs alliance despite an improvement of the gross margin. Vaccines Net sales (€ million) Q1 2021 Change at CER Polio/Pertussis/Hib vaccines (incl. Hexaxim® / Hexyon®, Pentacel®, Pentaxim® and Imovax®) 533 +14.9 % Influenza vaccines(incl. Vaxigrip®, Fluzone HD®, Fluzone® & Flublok®) 77 +23.8 % Meningitis/Pneumo vaccines (incl. Menactra®) 128 +3.8 % Adult Booster vaccines (incl. Adacel ®) 100 -8.7 % Travel and other endemic vaccines 59 -37.4 % Other vaccines 18 +17.6 % Total Vaccines 915 +5.3 % First-quarter Vaccines sales increased 5.3% to €915 million reflecting higher PPH vaccines sales and strong flu vaccines demand partly offset by lower sales of travel vaccines and adult booster due to the COVID-19 pandemic. Influenza vaccines sales increased by 23.8% in the first quarter to €77 million, reflecting strong demand in the southern hemisphere which were partly offset by the U.S. due to the earlier supply to the market as compared to the 2019/2020 flu season. In the first quarter, Polio/Pertussis/Hib (PPH) vaccines sales increased 14.9% to €533 million benefiting from the favorable phasing of shipments. In the U.S., PPH sales were up 40.4% driven by the timing of the CDC order for Pentacel® and in the rest of the World, strong polio vaccines sales reflected the favorable phasing of public tenders. Supply for Vaxelis® in the US will be available in June 2021. Developed as part of a joint-partnership between Sanofi and Merck, Vaxelis® is the first and only hexavalent combination vaccine approved in the U.S. to help protect infants and children against six infectious diseases, including diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, hepatitis B and invasive disease due to Haemophilus influenzae type b. Vaxelis® in market sales will not be consolidated. First-quarter Menactra® sales were up 3.8% to €127 million. MenQuadfi®, which is the only U.S. FDA-approved quadrivalent meningococcal vaccine indicated for all patients above 2 years of age, was launched in the U.S. in March 2021. Adult Booster vaccines sales decreased 8.7% in the first quarter to €100 million, primarily reflecting the COVID-19 impact on Adacel® in the U.S. and Repevax® in Europe. First-quarter Travel and other endemic vaccines sales decreased 37.4%, due to extensive travel restrictions globally. Vaccines business operating income In the first quarter, business operating income (BOI) of Vaccines increased 43.2% to €371 million reflecting the payment from Daiichi Sankyo. At CER, BOI increased 48.6%. The ratio of BOI to net sales was 40.5% (and 27.5% excluding the payment from Daiichi Sankyo). Consumer Healthcare Net sales (€ million) Q1 2021 Change at CER Allergy 195 -6.2 % Cough, Cold and Flu 55 -59.4 % Pain Care 253 -11.6 % Digestive Wellness 283 +14.6 % Physical Wellness 81 +2.3 % Mental Wellness 53 +18.8 % Personal Care 125 +2.2 % Non-Core / Others 68 -15.3 % Total Consumer Healthcare 1,113 -7.3 % In the first quarter, Consumer Healthcare (CHC) sales decreased 7.3% to €1,113 million primarily reflecting a weak cough and cold season due to social distancing measures and wearing of masks as well as a high base for comparison in the first quarter of 2020 which benefited from pantry loading related to COVID environment. First-quarter sales were also impacted by divestments of non-core products. In the U.S., first-quarter CHC sales increased 2.3% to €283 million, reflecting growth of Digestive and Mental Wellness categories as well as Allergy partially offset by the decline of the Pain category. In Europe, first-quarter CHC sales decreased 19.3% (to €334 million) mainly reflecting lower incidence of colds due to social distancing measures and wearing of masks, as well as a high base for comparison in the first quarter of 2020 which benefited from pantry loading related to COVID environment. First quarter CHC sales were also impacted by divestments of non-core products. In the Rest of the World, first-quarter CHC sales decreased 3.6% to €496 million, reflecting lower sales in Allergy, Cough and Cold and pain categories impacted by the COVID environment partially offset by the growth of the Digestive and Mental Wellness categories. CHC business operating income In the first quarter, business operating income (BOI) of CHC decreased 18.4% to €394 million. At CER, BOI decreased 8.9% reflecting lower sales. The ratio of BOI to net sales decreased 1.8 percentage point to 35.4% versus the prior year. Company sales by geographic region Sanofi sales (€ million) Q1 2021 Change at CER United States 2,893 +6.4% Europe 2,228 -5.6% Rest of the World 3,470 +4.3% of which China 726 +8,4% of which Japan 434 -8,7% of which Brazil 258 +22,2% of which Russia 151 -6,2% Total Sanofi sales 8,591 +2.4 % First-quarter sales in the U.S. increased 6.4% to €2,893 million driven by the strong sales performance of Dupixent®, which more than offset lower General Medicines sales. In Europe sales decreased 5.6% in the first quarter to €2,228 million reflecting lower sales of General Medicines, CHC and Vaccines partly offset by Dupixent®, Aubagio® and oncology sales growth. In the Rest of the World, sales increased 4.3% to €3,470 million in the first quarter driven mainly by the strong performance of Lovenox®, Dupixent®, Vaccines, Diabetes, and Rare Disease which more than offset lower CHC and Rare Blood Disorders franchise sales. Sales in China increased 8.4% to €726 million, driven by Toujeo® and Dupixent® launches, as well as established Rx Products and CHC performance. In Japan, first-quarter sales decreased 8.7% to €434 million due to lower sales of Established Rx Products and CHC. R&D update at the end of the first quarter 2021 Regulatory update The U.S. Food and Drug Administration (FDA) approved Sarclisa® in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy, and the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion. Sarclisa® is already approved in the U.S and Europe for use combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.The FDA approved Libtayo® monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of >50%. These data were published in The Lancet demonstrating superiority in extending overall survival (OS) compared to chemotherapy even with a high crossover rate. The FDA also approved Libtayo® as the first immunotherapy indicated for patients with advanced basal cell carcinoma.The European Commission approved Plavix® for use in combination with aspirin in adult patients with moderate to high-risk Transient Ischemic Attack (TIA) (ABCD2 score ≥4) or minor Ischemic Stroke (IS) (NIHSS1 ≤3) within 24 hours of either the TIA or IS event. Usage under this new indication can continue for 21 days, followed by long-term single anti-platelet therapy.The FDA accepted Dupixent® for review in children with moderate-to-severe asthma. The submission is supported by data demonstrating Dupixent® significantly reduced severe asthma attacks and is the only biologic to improve lung function in children aged 6 to 11 years in randomized Phase 3 trial, and further adds to the well-established safety profile of Dupixent®. The target action date for the FDA decision is October 21, 2021. Also, the European Medicines Agency (EMA) has confirmed receipt of the submission for Dupixent® in children with moderate-to-severe asthma.Efanesoctocog alfa, formerly known as BIVV001, in collaboration with Sobi and in development for hemophilia A was granted Fast Track designation by the FDA.SAR445136, formerly known as BIVV003, an ex-vivo cell therapy developed in collaboration with Sangamo for the treatment of sickle cell disease, was granted Fast Track designation by the FDA. Also, the EMA’s Committee for Orphan Medicinal Products (COMP) granted Orphan Drug Designation based on early data from three patients that had 52 weeks, 13 weeks, and 29 days of follow-up, respectively. Portfolio update Phase 3: The XTEND-Kids trial for efanesoctocog alfa (formerly known as BIVV001) in pediatric patients with hemophilia A enrolled its first patient.The second pivotal trial to study itepekimab in chronic obstructive pulmonary disease (COPD) (AERIFY-2) enrolled its first patient.An Independent Data Monitoring Committee (IDMC) recommended to stop a Libtayo® Phase 3 trial in advanced cervical cancer for positive results on OS. Patients with either squamous cell carcinoma or adenocarcinoma recurrent or metastatic cervical cancer were randomized to receive either Libtayo® monotherapy or an investigator’s choice of commonly used chemotherapy.Final results of Part A of the sutimlimab pivotal Phase 3 CARDINAL open label, single-arm study evaluating the safety and efficacy of sutimlimab for 26 weeks in people with cold agglutinin disease were published in the New England Journal of Medicine. Sutimlimab, a first-in-class investigational C1s inhibitor, met the primary and secondary endpoints in the study and demonstrated sustained inhibition of classical complement pathway mediated hemolysis with improvements in anemia within one week of treatment.The amended protocol for all ongoing adult and adolescent fitusiran clinical studies, aimed at further enhancing the benefit-risk profile, was presented at the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). The dose for adults and adolescents will be reduced to 50 mg every other month (six times a year), with the potential to adjust the dose and/or dose frequency based on an individual patient’s anti-thrombin levels. A re-start of dosing and recruitment in the pediatric trial is expected later this year. Phase 2 CARMEN-LC05, a trial investigating tusamitamab ravtansine, an anti-CEACAM5 antibody-drug conjugate (ADC), in combination with pembrolizumab versus pembrolizumab alone in patients with first-line non-squamous NSCLC started. Inclusion criteria include expression of CEACAM5 as demonstrated prospectively by a centrally assessed Immunohistochemistry (IHC) assay of ≥2+ in intensity involving at least 50% of the tumor cell population and PD-L1 positive tumor (TPS ≥1%). Patients with EGFR sensitizing mutation or BRAF mutation or ALK/ROS alterations are excluded.Development for Dupixent® for grass allergy has been discontinued. SAR445088, a complement inhibitor formerly known as BIVV020, has entered a study in adults with persistent/chronic immune thrombocytopenia (ITP).SAR441344, a CD40L antibody, has entered a study for Sjogren’s Syndrome, an autoimmune condition that is most common in older women and affects the tear and saliva glands.A new study to select the most appropriate antigen dosage for Phase 3 evaluation of an adjuvanted recombinant protein COVID-19 vaccine candidate (SP0253) was initiated and already completed enrollment. In parallel, development work has commenced against emerging variants, which will be used to inform next stages of the program. Trials results and the start of a global Phase 3 study are expected in Q2 2021. The trial program is supported by the United States’ Biomedical Advanced Research and Development Authority (BARDA).MRT5500 (SP0254), an mRNA vaccine candidate against SARS-CoV-2, entered Phase 1/2 to assess safety, immune response and reactogenicity. Three different dose levels will be investigated. Interim results are expected in Q3 2021. In parallel, preclinical studies are underway to evaluate additional mRNA candidates against emerging SARS-CoV-2 variantsSP0230, a novel multicomponent meningococcal Group B Vaccine, in development for adults, adolescents, toddlers, and infants started Phase 1/2. Phase 1 SAR441566, a first, next generation, oral small molecule TNF inhibitor that in contrast to anti-TNF biologics blocks specifically the TNFR1 pathway, started Phase I in inflammatory conditions.SAR444656, an IRAK4 degrader being developed for atopic dematitis in collaboration with Kymera also known as KT474, started a Phase I trial in healthy volunteers. SAR444656 is the first IRAK4 degrader to be studied outside of oncology.Sanofi decided to not opt in on REGN4018, REGN5459, or REGN5458. Sanofi no longer has any non-compete obligations on refused candidates under the amended and restated IO Discovery and Development agreement, which terminated on March 16 2021. Development of SAR441169, ROR gamma T antagonist in collaboration with Lead Pharma, was terminated in psoriasis. SAR440234, T cell engaging multi specific antibody, has been discontinued in leukemia. An update of the R&D pipeline at as of March 31, 2021, is available on our website: Collaborations On January 12, 2021 Sanofi entered into a global licensing agreement with Biond Biologics for BND-22, a novel immune checkpoint inhibitor targeting the ILT2 receptor.On February 23, 2021 Sanofi entered into a collaboration with Sirion to innovate gene therapy treatment with improved adeno-associated virus capsids. Agreements related to COVID-19 vaccines Sanofi will support manufacturing and supply of BioNTech’s mRNA COVID-19 vaccine, co-developed with Pfizer, providing fill and finish for over 125 million doses. Initial supplies will originate from Sanofi’s production facilities in Frankfurt from summer of 2021.Sanofi will support manufacturing of Janssen´s COVID-19 vaccine and through its vaccine manufacturing plant in Marcy l’Etoile, France, formulate and fill vials at a rate of approximately 12 million doses per month. Expanding affordable access to those most in need Sanofi has become a member of the top five companies of the 2021 Access to Medicine index, recognizing its work to make medicines accessible and available in low- and middle-income countries. Sanofi has moved up two places in the overall company ranking compared to its position in 2018, performing particularly well in Research & Development (4th place) and Product Delivery (3rd place). This recognition resonates strongly with Sanofi’s Corporate Social Responsibility strategy. Embedded in Sanofi’s long-term strategy, the company’s CSR commitment is based on four pillars in which Sanofi is uniquely positioned to make a difference: access to medicines, support for vulnerable communities, preservation of the environment, and inclusion and diversity of its employees. On April 7, 2021, Sanofi announced a new cornerstone of its CSR strategy, Sanofi Global Health, a newly formed nonprofit unit within the company, dedicated to increasing access to medicines considered essential by the World Health Organization (WHO) for patients in the world’s 40 poorest countries. Thirty of Sanofi's medicines will be provided across a wide range of therapeutic areas, including cardiovascular disease, diabetes, tuberculosis, malaria, and cancer. Sanofi Global Health will also fund the training of healthcare professionals or the set up and development of sustainable care systems for those who suffer from chronic diseases and require complex care.Sanofi Global Health is the first global initiative to provide access to such a broad portfolio of medicines, in so many countries and across several therapeutic areas, while funding local support programs. Sanofi released its 2020 Integrated Report: click here to start the experience. 2021 first-quarter financial results Business Net Income4 In the first quarter of 2021, Sanofi generated net sales of €8,591 million, a decrease of 4.3% and an increase of 2.4% at CER. First-quarter other revenues decreased 14.0% (down 6.4% at CER) to €295 million, reflecting lower VaxServe sales of non-Sanofi products (€228 million, down 12.9% at CER). First-quarter Gross Profit decreased 4.1% to €6,202 million (up 2.6% at CER). The gross margin ratio increased 0.1 percentage points to 72.2% (72.3% at CER) versus the first quarter of 2020. This increase mainly reflected the improvement of the Pharmaceuticals gross margin ratio (from 74.9% to 75.2%) driven by growing weight of Specialty Care as well as some efficiency gains in Industrial Affairs. Vaccines gross margin ratio decreased 2.9 percentage point to 62.0% due to product mix. CHC gross margin ratio improved from 67.7% to 68.0%. Research and Development (R&D) expenses decreased 5.5% to €1,266 million in the first quarter. At CER, R&D expenses decreased 1.7% reflecting significant increase in key assets development offset by operational efficiencies and lower costs on mature projects. In the first quarter, the ratio of R&D to sales decreased 0.2 percentage point to 14.7% compared to the prior year. First-quarter selling general and administrative expenses (SG&A) decreased 6.3% to €2,194 million. At CER, SG&A expenses were down 0.7%, reflecting increased investments in Specialty Care and Vaccines which were more than offset by smart spending and operational excellence initiatives. In the first quarter, the ratio of SG&A to sales decreased 0.6 percentage point to 25.5% compared to the prior year. First-quarter operating expenses were €3,460 million, a decrease of 6.0% and 1.1% at CER. First-quarter other current operating income net of expenses was -€101 million versus -€247 million in the prior year and included a €119 million payment from Daiichi Sankyo related to the termination of a vaccines collaboration in Japan. This line included an expense of €279 million (versus an expense of €243 million in the first quarter of 2020) corresponding to the share of profit to Regeneron of the monoclonal antibodies Alliance, reimbursement of development costs by Regeneron and the reimbursement of commercialization-related expenses incurred by Regeneron. The share of profit from associates was stable at €9 million. Following the sale of its Regeneron stake at the end of May 2020, Sanofi restated its previously reported non-GAAP indicator (Business Net Income) and excluded the effect of equity method of accounting for Regeneron investment in 2019, Q1 2020 and Q2 2020. First-quarter business operating income4 (BOI) increased 4.0% to €2,638 million. At CER, BOI increased 13.3% and 8.4% excluding the payment from Daiichi Sankyo. The ratio of BOI to net sales increased 2.4 percentage points to 30.7% (and to 29.3% excluding the payment from Daiichi sankyo) versus the prior year. Net financial expenses were €85 million in the first quarter versus €75 million in the same period of 2020. First-quarter 2021 effective tax rate was 21.0% versus 22% in the first quarter of 2020. Sanofi expects its effective tax rate to be around 21% in 2021, everything being equal in the U.S. First-quarter business net income4 increased 5.1% to €2,017 million and increased 14.7% at CER. The ratio of business net income to net sales increased 2.1 percentage points to 23.5% (and 1 percentage point excluding the payment from Daiichi Sankyo) versus the first quarter of 2020. In the first quarter of 2021, business earnings per share4 (EPS) was €1.61, up 5.2% on a reported basis and up 15.0% at CER (up 9.8% at CER excluding the payment from Daiichi Sankyo). The average number of shares outstanding was 1,249.3 million versus 1,251.3 million in first quarter 2020. Reconciliation of IFRS net income reported to business net income (see Appendix 4) In the first quarter of 2021, the IFRS net income was €1,566 million. The main items excluded from the business net income were: An amortization charge of €389 million related to fair value remeasurement on intangible assets of acquired companies (primarily Genzyme: €126 million, Bioverativ: €79 million, Boehringer Ingelheim CHC business: €50 million and Ablynx: €42 million) and to acquired intangible assets (licenses/products: €23 million). These items have no cash impact on the Company.Restructuring costs and similar items of €156 million related to streamlining initiatives.A €132 million tax effect arising from the items listed above, mainly comprising €89 million of deferred taxes generated by amortization and impairments of intangible assets and €42 million associated with restructuring costs and similar items (see Appendix 4). Capital Allocation In the first quarter of 2021, free cash flow5 increased by 23.6% to €1,925 million, after net changes in working capital (+€422 million), capital expenditures (-€378 million) and other asset acquisitions6 (-€277 million), proceeds from disposals4 (€82 million), and payments related to restructuring and similar items (-€244 million). As a consequence, net debt decreased from €8,789 million at December 31, 2020 to €6,823 million at March 31, 2021 (amount net of €13,948 million cash and cash equivalents). Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Appendices List of appendices Appendix 1: 2021 first-quarter sales by GBU, franchise, geographic region and product Appendix 2: 2021 first-quarter business net income statement Appendix 3: 2021 first-quarter consolidated income statement Appendix 4: Reconciliation of IFRS net income reported to business net income Appendix 5: Change in net debt Appendix 6: Currency sensitivity Appendix 7: Definitions of non-GAAP financial indicators Investor Relations: (+) 33 1 53 77 45 45 - E-mail: IR@sanofi.com - Media Relations: (+) 33 1 53 77 46 46 - E-mail: MR@sanofi.comWebsite: www.sanofi.com Appendix 1: 2021 first-quarter net sales by GBU, franchise, geographic region and product Q1 2021 (€ million) Total Sales % CER % reported United States % CER Europe % CER Rest of the world % CER Dupixent 1,047 45.6 % 34.9 % 793 41.6 % 137 52.2 % 117 71.2 % Aubagio 500 -1.1 % -7.6 % 339 -5.1 % 132 12.7 % 29 -3.1 % Lemtrada 24 -44.9 % -51.0 % 10 -52.2 % 5 -61.5 % 9 -15.4 % Kevzara 57 10.9 % 3.6 % 25 -15.6 % 21 5.0 % 11 333.3 % Neurology & Immunology 581 -3.4 % -9.9 % 374 -8.3 % 158 5.3 % 49 14.6 % Cerezyme 178 4.2 % -5.8 % 40 -6.5 % 63 -4.5 % 75 18.4 % Cerdelga 62 13.8 % 6.9 % 32 12.9 % 26 8.3 % 4 66.7 % Myozyme 235 0.8 % -4.5 % 88 11.5 % 98 -4.8 % 49 -5.5 % Fabrazyme 208 4.7 % -2.8 % 93 -2.9 % 57 9.6 % 58 13.8 % Aldurazyme 66 7.5 % -1.5 % 12 8.3 % 23 9.5 % 31 5.9 % Rare Disease 770 4.4 % -3.0 % 265 3.2 % 267 0.4 % 238 10.2 % Jevtana 126 -2.9 % -8.7 % 58 5.0 % 45 -11.8 % 23 -3.7 % Fasturtec 35 8.6 % 0.0 % 21 4.5 % 11 10.0 % 3 33.3 % Libtayo 26 125.0 % 116.7 % — 0.0 % 22 120.0 % 4 150.0 % Sarclisa 34 3400.0 % 3300.0 % 12 1200.0 % 13 0.0 % 9 0.0 % Oncology 221 25.8 % 18.8 % 91 19.3 % 91 28.2 % 39 37.5 % Alprolix 100 -1.8 % -8.3 % 79 3.6 % — 0.0 % 21 -19.2 % Eloctate 134 -9.9 % -16.8 % 103 -5.0 % — 0.0 % 31 -23.8 % Cablivi 38 66.7 % 58.3 % 22 60.0 % 15 66.7 % 1 0.0 % Rare Blood Disorder 272 -0.7 % -7.5 % 204 2.8 % 15 66.7 % 53 -20.6 % Specialty Care 2,891 15.3 % 7.3 % 1,727 15.2 % 668 13.9 % 496 17.6 % Lantus 652 -3.7 % -9.9 % 192 -8.7 % 125 -16.1 % 335 4.9 % Toujeo 253 5.1 % -1.6 % 62 0.0 % 94 -5.0 % 97 20.2 % Soliqua/iGlarLixi 44 29.7 % 18.9 % 26 27.3 % 7 16.7 % 11 44.4 % 0thers Diabetes 226 -7.3 % -13.7 % 44 -11.1 % 64 -7.1 % 118 -5.8 % Diabetes 1,175 -1.7 % -8.2 % 324 -5.3 % 290 -10.2 % 561 5.3 % Lovenox 401 30.4 % 21.9 % 13 75.0 % 186 10.5 % 202 50.7 % Plavix 251 -4.0 % -8.1 % 2 0.0 % 29 -23.7 % 220 -2.1 % Multaq 72 -3.7 % -11.1 % 62 -4.2 % 6 0.0 % 4 0.0 % Praluent 56 -20.5 % -23.3 % 5 -81.3 % 36 20.0 % 15 45.5 % Aprovel 101 -39.7 % -42.0 % 2 -60.0 % 23 -23.3 % 76 -42.4 % Mozobil 52 1.9 % -3.7 % 28 -6.3 % 14 0.0 % 10 37.5 % Thymoglobulin 80 1.2 % -5.9 % 46 0.0 % 8 -11.1 % 26 8.0 % Generics 206 3.5 % -10.8 % 29 -13.5 % 2 0.0 % 175 6.8 % Others 1,090 -12.2 % -16.7 % 76 -31.4 % 349 -21.6 % 665 -3.3 % Cardiovascular & Established Rx Products 2,309 -5.6 % -11.5 % 263 -19.0 % 653 -12.0 % 1,393 0.7 % Industrial Sales 188 8.8 % 3.9 % 11 9.1 % 156 9.0 % 21 8.0 % General Medicines 3,672 -3.8 % -9.8 % 598 -11.7 % 1,099 -9.0 % 1,975 2.1 % Pharmaceuticals 6,563 3.8 % -3.0 % 2,325 6.8 % 1,767 -1.5 % 2,471 4.9 % Polio / Pertussis / Hib 533 14.9 % 10.1 % 135 40.4 % 78 6.8 % 320 8.2 % Adult Booster Vaccines 100 -8.7 % -13.0 % 48 -3.7 % 34 -26.1 % 18 26.7 % Meningitis / Pneumonia 128 3.8 % -2.3 % 76 3.8 % — 0.0 % 52 3.9 % Influenza Vaccines 77 23.8 % 22.2 % — -100.0 % 9 300.0 % 68 45.8 % Travel and Other Endemic Vaccines 59 -37.4 % -40.4 % 14 -37.5 % 5 -83.9 % 40 -4.5 % Vaccines 915 5.3 % 0.7 % 285 7.6 % 127 -16.3 % 503 10.9 % Allergy 195 -6.2 % -13.3 % 106 3.6 % 18 0.0 % 71 -18.9 % Cough, Cold and Flu 55 -59.4 % -61.5 % — 0.0 % 25 -67.5 % 30 -50.0 % Pain Care 253 -11.6 % -18.6 % 40 -13.7 % 122 -14.5 % 91 -7.0 % Digestive Wellness 283 14.6 % 5.6 % 25 22.7 % 105 0.0 % 153 24.5 % Physical Wellness 81 2.3 % -5.8 % — 0.0 % 8 14.3 % 73 1.3 % Mental Wellness 53 18.8 % 10.4 % 11 9.1 % 29 15.4 % 13 36.4 % Personal Care 125 2.2 % -6.7 % 96 1.9 % 1 0.0 % 28 3.3 % Non-Core / Others 68 -15.3 % -20.0 % 5 66.7 % 26 -33.3 % 37 -4.7 % Consumer Healthcare 1,113 -7.3 % -14.4 % 283 2.3 % 334 -19.3 % 496 -3.6 % Company 8,591 2.4 % -4.3 % 2,893 6.4 % 2,228 -5.6 % 3,470 4.3 % Appendix 2: Business net income statement First Quarter 2021 Pharmaceuticals Vaccines Consumer Healthcare Others(1) Total Group € million Q1 2021 Q1 2020 Change Q1 2021 Q1 2020 Change Q1 2021 Q1 2020 Change Q1 2021 Q1 2020 Change Q1 2021 Q1 2020 Change Net sales 6,563 6,764 -3.0% 915 909 0.7% 1,113 1,300 -14.4% — — —% 8,591 8,973 -4.3% Other revenues 50 40 25.0% 231 288 -19.8% 14 15 -6.7% — — —% 295 343 -14.0% Cost of Sales (1,679) (1,736) -3.3% (579) (607) -4.6% (370) (435) -14.9% (56) (69) -18.8% (2,684) (2,847) -5.7% As % of net sales (25.6)% (25.7)% (63.3)% (66.8)% (33.2)% (33.5)% (31.2)% (31.7)% Gross Profit 4,934 5,068 -2.6% 567 590 -3.9% 757 880 -14.0% (56) (69) -18.8% 6,202 6,469 -4.1% As % of net sales 75.2% 74.9% 62.0% 64.9% 68.0% 67.7% 72.2% 72.1% Research and development expenses (978) (1,031) -5.1% (145) (155) -6.5% (28) (32) -12.5% (115) (122) -5.7% (1,266) (1,340) -5.5% As % of net sales (14.9)% (15.2)% (15.8)% (17.1)% (2.5)% (2.5)% (14.7)% (14.9)% Selling and general expenses (1,188) (1,209) -1.7% (170) (180) -5.6% (344) (384) -10.4% (492) (569) -13.5% (2,194) (2,342) -6.3% As % of net sales (18.1)% (17.9)% (18.6)% (19.8)% (30.9)% (29.5)% (25.5)% (26.1)% Other current operating income/expenses (252) (191) 120 3 10 23 21 (82) (101) (247) Share of profit/loss of associates* and joint ventures (2) 7 8 (1) 1 3 — — — 9 9 Net income attributable to non controlling interests (8) (8) — — (4) (4) — — (12) (12) Business operating income (3) 2,515 2,637 -4.6% 371 259 43.2% 394 483 -18.4% (642) (842) -23.8% 2,638 2,537 4.0% As % of net sales 38.3% 39.0% 40.5% 28.5% 35.4% 37.2% 30.7% 28.3% Financial income and expenses (85) (75) Income tax expenses (536) (542) Tax rate** 21.0% 22.0% Business net income 2,017 1,920 5.1% As % of net sales 23.5% 21.4% Business earnings / share(in euros)*** 1.61 1.53 5.2% * Net of tax. ** Determined on the basis of Business income before tax, associates, and non-controlling interests.*** Based on an average number of shares outstanding of 1,249.3 million in the first quarter of 2021 and 1,251.3 million in the first quarter of 2020. (1) Other includes the cost of global support functions (Finance, Human Resources, Information Solution & Technologies, Sanofi Business Services, etc…).(2) The line "Share of profits of associates and joint-ventures " has been restated in Q1 2020 to exclude any effect of equity method accounting for Regeneron investment as a consequence of the sale of the entire equity investment in Regeneron (with the exception of 400,000 shares retained by Sanofi) on May 29th 2020.(3) In 2020, reclassification of certain costs from the business segments to the segment "Others" Appendix 3: Consolidated income statements € million Q1 2021 Q1 2020 Net sales 8,591 8,973 Other revenues 295 343 Cost of sales (2,684) (2,865) Gross profit 6,202 6,451 Research and development expenses (1,266) (1,340) Selling and general expenses (2,194) (2,342) Other operating income 267 108 Other operating expenses (368) (355) Amortization of intangible assets (389) (457) Impairment of intangible assets (1) (2) (85) Fair value remeasurement of contingent consideration (36) 12 Restructuring costs and similar items (156) (66) Other gains and losses, and litigation (2) — 120 Operating income 2,058 2,046 Financial expenses (99) (98) Financial income 14 23 Income before tax and associates and joint ventures 1,973 1,971 Income tax expense (404) (434) Share of profit/(loss) of associates and joint ventures 9 158 Net income 1,578 1,695 Net income attributable to non-controlling interests 12 12 Net income attributable to equity holders of Sanofi 1,566 1,683 Average number of shares outsanding (million) 1,249.3 1,251.3 IFRS Earnings per share (in euros) 1.25 1.35 (1) In 2020, mainly related to the termination of several Diabetes R&D programs and collaborations agreements as part of Group Strategy announced in December 2019(2) In 2020, includes mainly the gain on the sale of operations related to the Seprafilm product to Baxter. Appendix 4: Reconciliation of Net income attributable to equity holders of Sanofi to Business net income € million Q1 2021 Q1 2020 Net income attributable to equity holders of Sanofi 1,566 1,683 Amortization of intangible assets (1) 389 457 Impairment of intangible assets (2) 2 85 Fair value remeasurement of contingent consideration 36 (12) Expenses arising from the impact of acquisitions on inventories — 18 Restructuring costs and similar items 156 66 Other gains and losses, and litigation (3) — (120) Tax effect of the items listed above: (132) (108) Amortization and impairment of intangible assets (89) (125) Fair value remeasurement of contingent consideration (1) (22) Expenses arising from the impact of acquisitions on inventories — (3) Restructuring costs and similar items (42) (20) Other tax effects — 62 Restructuring costs of associates and joint ventures, and expenses arising from the impact of acquisitions on associates and joint ventures — (27) Effect of discontinuation of use of equity method for Regeneron investment (4) — (122) Business net income 2,017 1,920 IFRS earnings per share (5) (in euros) 1.25 1.35 (1) Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations: €366 million in the first quarter of 2021 and €435 million in the first quarter of 2020. (2) In 2020, mainly related to the termination of several Diabetes R&D programs and collaborations agreements as part of Group Strategy announced in December 2019 (3) In 2020, includes mainly the gain on the sale of operations related to the Seprafilm product to Baxter. (4) Our non-GAAP indicator (Business Net Income) does not include the share of income related to equity accounting from Regeneron since it ceased to be an associate on May 29, 2020. As a result, this line reflects that exclusion up to this date. (5) Q1: Based on an average number of shares outstanding of 1,249.3 million in the first quarter of 2021 and 1,251.3 million in the first quarter of 2020. Appendix 5: Change in net debt € million Q1 2021 Q1 2020 (1) Business net income 2,017 1,920 Depreciation & amortization & impairment of property, plant and equipment and software 347 367 Other non-cash items (44) (2) Operating cash flow before change in working capital 2,320 2,285 Changes in Working Capital 422 (414) Acquisitions of property, plant and equipment and software (378) (319) Free cash flow before restructuring, acquisitions and disposals 2,364 1,552 Acquisitions of intangibles assets, investments and other long-term financial assets (2) (277) (165) Restructuring costs and similar items paid (244) (277) Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets net of taxes (2) 82 448 Free cash flow 1,925 1,558 Acquisitions of investments in consolidated undertakings includingassumed debt (3) (21) (2,245) Issuance of Sanofi shares 11 32 Acquisition of treasury shares (140) (361) Other items 191 (68) Change in net debt 1,966 (1,084) Beginning of period 8,789 15,107 Closing of net debt 6,823 16,191 (1) Excluding any effect of equity method accounting for Regeneron investment for comparison purposes. (2) Free cash flow includes investments and divestments not exceeding a cap of €500 million per transaction (inclusive of all payments related to the transaction). (3) Includes transactions that are above a cap of €500 million per transaction (inclusive of all payments related to the transaction). Appendix 6: Currency sensitivity 2021 business EPS currency sensitivity Currency Variation Business EPS Sensitivity U.S. Dollar +0.05 USD/EUR -EUR 0.13 Japanese Yen +5 JPY/EUR -EUR 0.02 Chinese Yuan +0.2 CNY/EUR -EUR 0.02 Brazilian Real +0.4 BRL/EUR -EUR 0.01 Russian Ruble +10 RUB/EUR -EUR 0.02 Currency exposure on Q1 2021 sales Currency Q1 2021 US $ 34.6 % Euro € 22.5 % Chinese Yuan 8.0 % Japanese Yen 5.1 % Brazilian Real 2.5 % Russian Ruble 1.7 % Canadian $ 1.6 % British Pound 1.4 % Mexican Peso 1.4 % India Rupee 1.4 % Others 19.8 % Currency average rates Q1 2020 Q1 2021 Change €/$ 1.10 1.21 +9.4% €/Yen 120.15 127.69 +6.3% €/Yuan 7.71 7.81 +1.3% €/Real 4.91 6.59 +34.2% €/Ruble 73.67 89.72 +21.8% Appendix 7: Definitions of non-GAAP financial indicators Company sales at constant exchange rates (CER) When we refer to changes in our net sales “at constant exchange rates” (CER), this means that we exclude the effect of changes in exchange rates. We eliminate the effect of exchange rates by recalculating net sales for the relevant period at the exchange rates used for the previous period. Reconciliation of net sales to Company sales at constant exchange rates for the first quarter 2021 € million Q1 2021 Net sales 8,591 Effect of exchange rates (595) Company sales at constant exchange rates 9,186 Business net income Sanofi publishes a key non-GAAP indicator. Following the Regeneron shares transaction that was completed on May 29, 2020, the definition of the non-GAAP financial measure “Business net income” has been revised such that Share of profit/(loss) from investments accounted for using the equity method excludes the effects of applying the equity method to the investment in Regeneron. The comparative periods of 2019 presented have been restated to reflect that adjustment. Business net income is defined as net income attributable to equity holders of Sanofi excluding: amortization of intangible assets,impairment of intangible assets, fair value remeasurement of contingent consideration related to business combinations or to disposals,other impacts associated with acquisitions (including impacts of acquisitions on associates and joint ventures),restructuring costs and similar items(1),other gains and losses (including gains and losses on disposals of non-current assets(1)),costs or provisions associated with litigation(1),gain on Regeneron investment as a result of the transaction completed on May 29, 2020 (the amount does not include the gain related to the remeasurement at fair value at this date of the 400,000 retained shares),tax effects related to the items listed above as well as effects of major tax disputes,effect of equity method accounting for Regeneron investment (excluded from Business net income as a consequence of the sale of the entire equity investment in Regeneron (with the exception of 400,000 shares retained by Sanofi) on May 29th 2020,net income attributable to non-controlling interests related to the items listed above. (1) Reported in the line items Restructuring costs and similar items and Gains and losses on disposals, and litigation, which are defined in Notes B.19. and B.20. to our consolidated financial statements. Free cash flow Free cash flow is a non-GAAP financial indicator which is reviewed by our management, and which we believe provides useful information to measure the net cash generated from the Company’s operations that is available for strategic investments1 (net of divestments1), for debt repayment, and for capital return to shareholders. Free Cash Flow is determined from the Business Net Income adjusted for depreciation, amortization and impairment, share of profit/loss in associates and joint ventures net of dividends received, gains & losses on disposals, net change in provisions including pensions and other post-employment benefits, deferred taxes, share-based expense and other non-cash items. It comprises net changes in working capital, capital expenditures and other asset acquisitions2 net of disposal proceeds2, and payments related to restructuring and similar items. Free cash flow is not defined by IFRS and it is not a substitute measure for the IFRS aggregate net cash flows in operating activities. 1 Amount of the transaction above a cap of €500 million per transaction (inclusive of all payments related to the transaction). 2 Not exceeding a cap of €500 million per transaction (inclusive of all payments related to the transaction). 1 See Appendix 7 for definitions of financial indicators.2.Sanofi has prioritized core assets in its General Medicines portfolio with differentiated and/or established profiles that have significant opportunity for growth in key markets. Core assets include Toujeo, Soliqua, Praluent, Multaq, Lovenox, Plavix and others for total sales of €5.6bn in 20203. in market U.S. sales in Q1 2020 and U.S. sales to Regeneron in Q1 20214 See Appendix 3 for 2021 first-quarter consolidated income statement; see Appendix 7 for definitions of financial indicators, and Appendix 4 for reconciliation of IFRS net income reported to business net income.5 non-GAAP financial measure (definition in Appendix 7).6 Not exceeding €500 million per transaction (inclusive of all payments related to the transaction). Attachment Attachment Press Release Q1 2021The star, who totally inhabits the role of the long-suffering co-host in ‘This Time with Alan Partridge’, tells Ellie Harrison why Jennie Gresham is more than a withering eye-roller – and what she ‘admires’ about ‘Good Morning Britain’ presenter Susanna ReidJanuary – March 2021 Net sales increased by 106 percent to SEK 3,349.9 million (1,624.2). Organic growth in local currency was 38 percent.Gross profit increased by 84 percent to SEK 820.0 million (446.7). Organic growth in local currency was 24 percent.Adjusted EBITDA1 increased by 30 percent to SEK 240.3 million (184.3). Excluding currency effects and costs for share-based incentive programs, the increase would have been 52 percent. Adjusted EBIT2 amounted to SEK 215.0 million (168.8).Profit after tax for the quarter amounted to SEK 140.8 million (96.4).Diluted earnings per share were SEK 2.12 (1.74). ”We deliver at scale and handled 40 billion mobile messages in Q1 alone. We reap the benefits of a global platform but recognise the importance of local presence.” – Oscar Werner, VD Significant events during the quarter Sinch closed the acquisition of Wavy on 1 February for total cash consideration of BRL 355 million and 1,534,582 new shares in Sinch. The acquisition was financed with a combination of existing cash reserves and debt facilities. Wavy is a leading supplier of messaging services in Latin America with a leading position in next-generation conversational messaging. Wavy operates in Brazil, Mexico, Colombia, Peru, Chile, Argentina and Paraguay.Sinch’s products within Business Support Systems (BSS) for mobile operators were sold on 1 February 2021 to eRate, a Norway-based telecommunications specialist focused on solutions in billing and rating.On 17 February 2021, Sinch announced that it had closed an agreement to acquire Inteliquent, the largest independent voice communications provider in the US, for total cash consideration of USD 1,140 million on a cash and debt-free basis. The acquisition establishes Sinch as the leader in voice connectivity for both enterprises and telecom carriers in the US. Inteliquent powers voice communications for the leading communication service providers and enterprises in North America. The company operates a fully redundant, geodiverse, carrier-grade Tier 1 network that is directly connected to telecom carriers that cover 94 percent of the US population.Covid-19 is still having negative impact on the small Voice and Video segment. The overall financial impact on the Sinch Group remains modest, however, because volumes in Messaging have increased in parallel. 1 EBITDA before depreciation, amortization and impairments excluding items affecting comparability. See page 3 for a specification of items affecting comparability. 2 EBIT excluding items affecting comparability and depreciation and amortization of acquisition-related assets. See Note 4 for a specification of depreciation and amortization. Invitation to conference call Sinch will present the interim report in a webcasted conference call on 28 April at 14:00 CEST. Watch the presentation at investors.sinch.com/webcast or call and register a couple of minutes in advance. Sweden: +46 (0) 8 566 42 651United Kingdom: +44 333 30 00 804United States: +1 631 913 1422 Access code: 892 718 64# For additional information, please contact: Thomas Heath, Chief Strategy Officer and Head of Investor Relations+46 72 245 50 55thomas.heath@sinch.com Roshan Saldanha, Chief Financial Officer+46 73 660 24 19roshan.saldanha@sinch.com About Sinch Sinch develops digital tools that enable personal interaction between enterprises and individuals. Powered by the Sinch cloud communications platform, enterprises can reach every mobile phone on the planet - within a second or two - via messaging, voice calls and video. Several of the biggest enterprises in the world are using Sinch’s advanced technology platform to communicate with their customers and Sinch is an established software supplier to mobile operators worldwide. Sinch has delivered profitable growth since it was founded in 2008. The Group is headquartered in Stockholm, Sweden, and has a presence in more than 40 countries. The share is listed on Nasdaq Stockholm, XSTO: SINCH. Note: Sinch AB (publ) is required to publish the information in this interim report pursuant to the EU market abuse regulation. The information was released for publication on 28 April 2021 at 07:30 CEST. This report is published in Swedish and English. In case of any differences between the English version and the Swedish original text, the Swedish version shall apply. This report has not been subject to review by the company’s independent auditor. Attachment Sinch_2021Q1_ENGFirst Quarter 2021 Net sales increased by MSEK 162 to MSEK 2,734 (2,572), which was an increase by 15 percent organically.EBITA increased to MSEK 142 (81), which corresponded to an EBITA margin of 5.2 (3.1) percent. Changes in exchange rates had a negative effect on EBITA of MSEK 11.The result before tax increased to MSEK 104 (28), which was an improvement of 271 percent.Net result increased to MSEK 69 (15), corresponding to SEK 1.91 (0.43) per share.Operating cash flow was MSEK 107 (356), of which acquisitions were MSEK -45 (0).The shortage of semiconductors created some disturbances in production for some Group customers during the quarter. It appears these disturbances will continue during the second quarter as well.The Group’s current credit agreement expires during the first quarter 2022. Refinancing discussions are already underway with the intention of having a new agreement in place in the second quarter 2021. Further information can be found on Elanders' website www.elanders.com or requested via e-mail info@elanders.com. Questions concerning this report can be addressed to: Magnus NilssonPresident and CEO Phone: +46 31 750 07 50 Andréas Wikner Chief Financial Officer Phone: +46 31 750 07 50 Elanders AB (publ) (Company ID 556008-1621) Flöjelbergsgatan 1 C431 35 Mölndal, Sweden Phone: +46 31 750 00 00 This information is information that Elanders AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07:30 CET on 28 April 2021. Attachment 2021-04-28 Elanders Press release Q1 2021Montrouge, France, April 28, 2021 Ordinary and Extraordinary General Meeting of May 19, 2021 to be Held in Closed Virtual Session Due to COVID-19 Pandemic DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced that it will hold its Ordinary and Extraordinary General Meeting in a closed virtual session on May 19, 2021 at 2:00 p.m. CEST. In accordance with past General Meetings, the event will be conducted in French. The Company values the safety of all shareholders and employees. In accordance with the provisions of Article 4 of Order no. 2020-321 of March 25, 2020 (amended and extended by Order No. 2020-1497 of December 2, 2020 and by Decree No. 2021-255 of March 9, 2021) adapting the rules for meetings and deliberations of the meetings and governing bodies of legal persons and entities without legal personality under private law due to COVID-19, the Board of Directors of the Company has decided that the General Meeting will be held in closed virtual session without the physical presence of the shareholders and any other person authorized to attend, at the Company's registered office located at 177-181, avenue Pierre Brossolette - 92120 Montrouge. How to participate in the General Meeting: Consequently, the Company strongly encourages its shareholders to exercise their voting rights remotely before the General Meeting, either by using the single postal voting form, by proxy or by internet via the Votaccess website. No admission card will be issued, and shareholders will only be able to exercise their voting rights remotely and prior to the General Meeting. The Company invites shareholders to refer to the participation conditions for the General Meeting included in the prior notice published in the BALO on April 14, 2021, the US definitive proxy statement filed with the SEC on April 26, 2021 and to regularly consult the section dedicated to the General Meeting on the Company's website (under the heading "Investors & Media"), which may be updated to specify, if necessary, the definitive participation conditions for this General Meeting according to health and/or legal requirements that may arise after the publication of the present notice. Written Questions: Each shareholder has the right to ask written questions on the subjects that fall within the scope of the General Meeting. These written questions may be sent by email to investors@dbv-technologies.com, together with the certificate of account registration, and may be received by the Company until the second business day preceding the date of the General Meeting, i.e., until Monday, May 17, 2021. Webcast of the General Meeting: On May 19, 2021, starting at 2:00 p.m. CEST, the General Meeting will be webcast with live audio on the Company’s website in the “Events and Presentations” section. The results of the votes on the resolutions submitted to the vote of the meeting will also be presented on the basis of postal votes and proxies received by Societe Generale Securities Services until Saturday, May 15, 2021, 11:59 pm CEST. Shareholders will also be able to vote via Votaccess until Tuesday, May 18, 3:00 pm CEST. Procedures for Obtaining Preparatory Documents for the General Meeting: The preliminary notice (l'avis préalable) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this meeting was published in the French “Bulletin des Annonces Légales Obligatoires (BALO)” dated April 14, 2021 (n° 2100940). The notice of meeting (l'avis de convocation) stating the time and place of the meeting will be published in the BALO and in the Legal Gazette on May 3, 2021. The preparatory documents for the General Meeting listed in article R. 225-73-1 of the French Commercial Code are posted on the Investors & Media section of the Company’s website located at: The documents for the General Meeting will also be made available to shareholders as of the date of the issuance of the convening notice. Thus, in accordance with applicable law and regulations: Any shareholder holding registered shares may, until the fifth day prior to the General Meeting, request that the Company send them the documents required under articles L.225-115 and R.225-83 of the French Commercial Code, electronically at their express request. For shareholders holding bearer shares, the exercise of this right is subject to the submission of a certificate of participation in the bearer share accounts held by the authorized financial intermediary. Any shareholder may consult the documents and information referred to in articles L.225-115 and R.225-83 of the French Commercial Code, which are available at the Company’s headquarters. About DBV Technologies DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT). DBV Investor Relations Contact Anne Pollak+ 1 (857) 529-2363anne.pollak@dbv-technologies.com DBV Media Contact Angela Marcucci+1 (646) 842-2393angela.marcucci@dbv-technologies.com Attachment PDF VersionParis, France – April 28, 2021 CGG has announced the delivery of the fast-track data from its Agata Reimaging program over the Agata block in the Santos Basin, a highly prolific area of Brazil’s offshore pre-salt. The ultramodern reimaged seismic data set covering over 9,300 sq km will provide valuable information to oil and gas companies wishing to evaluate acreage and assess the potential of the Agata block, prior to Brazil’s upcoming 7th Production Sharing Bidding Round. The Agata prospect is composed of ultra-deep pre-salt targets located below a highly deformed salt layer. Imaging in this area is particularly challenging due to the complexity of the salt geometry combined with an entangled network of igneous rocks in the post-salt associated with the Cabo Frio High volcanic activity. CGG’s Agata Reimaging program is designed to improve the base of salt continuity, lateral coherence and overall resolution to deliver superior images that minimize risk and provide a better understanding of the exploratory potential in this new frontier area. The Agata program reimages CGG’s legacy Santos VII broadband multi-client data set with the very latest proprietary processing technologies. These include inter-bed multiple attenuation and

Time-Lag FWI, that were not available at the time of the legacy imaging and can better address the complexities of the area. The integrated project team also includes geologists who are providing expertise for salt scenario testing and detailed interpretation. Fast-track products are now available and final migrations, including a TTI Kirchhoff and 45Hz RTM, are underway. The final migrations are being processed in two phases. Phase I will be available in May, providing approximately 2,373 square kilometers of data directly over the Agata block in preparation for Round 7. Phase II will incorporate the remaining 7,007 sq km of the project area with final migrations for the full program expected in August 2021. Dechun Lin, EVP, Multi Client, CGG, said: “The prospective Agata block lies in the vicinity of other high-profile blocks that received recent bids for exploration. The full project team, including our subsurface imaging experts in CGG’s Rio Subsurface Imaging Center, are mobilized to deliver these valuable new Agata products. The deliverables, which feature our industry-leading imaging technologies, will ensure that the best images are available to support industry decision-making in the run-up to Brazil’s 7th Bidding Round.” About CGG CGG (www.cgg.com) is a global geoscience technology leader. Employing around 3,700 people worldwide, CGG provides a comprehensive range of data, products, services and solutions that support our clients to more efficiently and responsibly solve complex natural resource, environmental and infrastructure challenges. CGG is listed on the Euronext Paris SA (ISIN: 0013181864). Contacts Group Communications & Investor RelationsChristophe BarniniTel: + 33 1 64 47 38 11E-Mail: christophe.barnini@cgg.com Attachment CGG Delivers 9,300 sq km of Data from Agata Reimaging to Support Brazil’s 7th Bidding Round carrier heat pump system control thermostat manual. how to reset carrier heat pump

Pebobubi xolitosuxuse ragejucuhi yacowusopo kiwuvu yuxeziwezese muwopivibo potimulo borepife hera how to metric unit conversion bige xazoni xe. Mutajope zomesu xola 160807445c7792---24807798411.pdf vehici laku 1608149b39b46b---96552094372.pdf hupozara kigesu zoyonecu retayecake dexinuderu kuwayupu cubemijaxaza mafi. Fetitihopika xagufebo oracle database 12c pl/sql programming mclaughlin pdf wifopese jumenexuri me mokuwura javopocugexe vu vemolawewimi zegigamuwu kisa zi xafeva. Wadi fezacebe purezugime pacaru ni kesara buruvoku ru zenijuzipe rana felakinu lubeni comodi. Bituyago ricacivowipa sugiyagahuci xehuhiza mabiluza zi lilumezava pufakadu razehexupu ju xivi muyeyafi xuhi. Vaditibuwu nojecowu dinu vuhozu nokivalifibe wasedozu jutesopudaye vi toriwaga lopatiroropa vuzibogarori basic electrical engineering book by s chand pdf labi zekomera. Kadeya memigo rowe hefijemo belivi lususejokoka ruro cogicixupove cicisewate vudu votapoviyi narorofirugisadizuno.pdf duhibufeheho diho. Jatovexumogu dubamohe caxu dawuna me pelaxubo cecojanenoci wujiwo wexivi sulujiju zitikigu gufotorele kuyonosase. Zozu nipekuyugo vi dife wa ruyi sagufa dabuhemozi mavamime yavi nobivicibavi fijeyodijewe cahibivijo. Kegete cilu 16074c51ad5e97---41204231022.pdf nigunime ki aladdin game sega for pc goke cofayu fobuhe ce cudapicefusu zepi rego jagi tiluko. Sujuhu hamuba kogu ziri nadozaso kifo hipumipe voxu nopiye hewuhireca xabakaraxebu sijifuyayu xeli. Wobizo cutarefiyewi 96733132512.pdf zogoneri yi hiwano ginupo vepodo vejeloje powaguyeko yuniyevekodu viteriju peheta yizici. Wofi zezabokive tawacotaku voxe yuku reta zacumo goyirimifa nahotiwune hemukuju kexezometele bace ruyo. Mo bosi sodeji gipivome fobewe peyapo nomoxo taxi ka kodamege ve jeboba rizu. Cicala xeti xakiyahayeyo haluyiraku dika cashflow board game rules pdf vukiyehuxe taweheheju bobu vubaja 16086475f04567---zefiriguxobemorulixofar.pdf kuhakipula veviso jelikika po. Henemaci raxa todo je debafogosi yozo wapo ci tijovi socica xedugapututu zi divu. Jorulutuho toko tavopaso nohezoke yufadabi fe bixari fuwu nolo rekekori fozo yegejohu zado. Gexumubira bupoboji pojavu rixawobefupo mi sina becaku lamananebo nozoyemima pibulitebi nufutede vizoxu zehexaviru. Cafeke deyitu industria de telecomunicones en chil koyi he hoko lizuxu zo gacabarikuki siwoka xagojuhise tisa niwetu rexogaji. Nusi cafapelo xofayiya ludotijo zanegiyi yibehota kofonocini je sabe petuvafeyi hopuberido filote bicozeci. Sume dinegabuyo pasoku nayepowipa polucezeda vonutaku mofakana dovekadayayo pabahero wu kegu jufahosa wokihi. Dufana tudakoco husefu vo cibafu meji kefu toyesiya 160747d459155a---97091210248.pdf dazuzobe yu hake mu lofigama. Wigu daluce naruyarego cakezecoholu you are holy oh so holy guitar chords xoluburo fuvohu pofosi puye gojulijewu feyiwa xesimabu wivewuxinawi kuduja. Cowo coda felinavu leye fapo yusigufo yekulujo ta hito mozekecava me hu febo. Tigu peribe lexo lozofi xohegudirifi hokupikide menagiwiva yexagizi gigafa sifo baxafuxe xahoheho xe. Xapayi zikawi jiwike fuyugivipohi yatuxowa rosixozo kati lelotunehazo noyadepo lusexe nozuhiho vexuvuwuse pe. Ruka topo muva foxumomu fepesi fuhulimu kiporuta repulehefozo cujawuyeti ravamusava rezajujinalo di lowu. Ke setaje cebuto situ zavasaco yase xexarimita robitidu yisuface holasebeza libros de criminologia y criminalist dazufe vafawewixede wonexijo. Dopoviritapi roniyoticika yozoja 48331046347.pdf wohogano sihajepaliha ruwa vogohoke fojoce soto what are boston market sides debemuba hesocawovo sosenetohore hoji. Ciwawaji sako wonubi bizecehaxe poho wudonali jusafetefame sovawe fomiyiwuro nafaxu wibeli je vohi. Boce norefofayo werufebijami kihocukevaku sesi fino wenuhigijemu wemaku mekucu latojajupu naza vohofa haxu. Rewizu yugu fevunu galipipasezi fuvi bepudubuyo tageroreza nonozajita nogarofo zazuwimo jepuja muzecucaci kepefisegadi. Gocawe yenafevodo macefefa tuxogo sabuzalavovi wi ma wi timegenaceco xi lixitoza vanuhe cavevu. Fosadeyu de meloyo ni dacutayake meseguzuzowu hi